Clinical Trials

Clinical Research

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. Clinical research includes trials that test new treatments and therapies, genetic studies to explore ways in which a person’s genes may contribute to developing a disorder and epidemiological studies to understand the patterns, causes, and effects of health and disease. 

Clinical Trials

Human clinical trials are a critical phase to bringing safe and effective treatments to market. Many tests are conducted before the clinical trial stage to determine whether potential treatments are appropriate for testing in people. It is through clinical trials that safe and effective drugs, therapies and ultimately, a cure for alopecia areata will be discovered. By participating in a clinical trial, you play an important role in the fight to treat and cure alopecia areata. The decision to participate, however, is very personal and should be made only after speaking with your health care provider and other individuals you trust. You can stop participation in a clinical trial at any time if new concerns arise or you lose confidence that its potential benefits outweigh its risks.

Clinical Trial Resources

ClinicalTrials.gov offers up-to-date information for locating federally and privately supported clinical trials for a wide range of diseases and conditions. Visit ClinicalTrials.gov to review clinical trials that are enrolling around the country on alopecia areata and other diseases.

Clinical Trials and Research Studies

The National Alopecia Areata Foundation is committed to delivering accurate and reliable information to everyone affected by alopecia areata, and subsequently reviews many requests for participation in research studies. The following is a current list of other research studies seeking to recruit people with alopecia areata. 

Disclaimer: NAAF provides research notices as an informational service to its community. NAAF is not conducting the study. This information does not represent a NAAF endorsement, but rather makes you aware that clinical studies are available for your participation if you choose. If you are presently under the care of a physician for alopecia areata, or other conditions, you should discuss this study with your doctor before altering your treatment program. NAAF is not responsible for any adverse outcomes.

Self-help for visible skin difference in adults

Last Updated:
01/19/2017
Status:
Active/Fully Enrolled
Country:
United Kingdom
Eligibility:
Age 18+; living with alopecia areata, totalis or universalis
Sponsor: 
University of Sheffield
A research study being conducted by researchers from the Department of Psychology at the University of Sheffield is seeking to find out whether a self-help intervention is effective for adults with a visible skin difference. The self-help intervention aims to help people build their confidence in social situations. If your confidence in social situations is affected by your visible skin difference and you are aged 18 or over, you are eligible to participate. Participants in the study will be asked to complete a set of questionnaires. These will be repeated once during the course of the study...Read more

LEO 124249 Ointment in the Treatment of Alopecia Areata

Last Updated:
08/16/2016
Status:
Completed
Country:
United States
Drug:
LEO 124249 Ointment
Administration:
Topical
Eligibility:
Age 18-65; diagnosed with moderate to severe patch type alopecia areata
Sponsor: 
LEO Pharma
The purpose of this study is to investigate the efficacy and safety of LEO 124249 in the treatment of alopecia areata. The following research centers are looking for volunteers to participate in this study that will use an investigational topical product for alopecia areata: Northwestern University Evanston, Illinois Phone: 312-695-3613 The Icahn School of Medicine, Mount Sinai Hospital New York, New York Phone: 212-241-3288Read more

A Study of the Impact of Alopecia Areata on Patients and Families

Last Updated:
07/26/2016
Status:
Completed
Country:
United States
Eligibility:
Living with alopecia areata, totalis or universalis; Parent, spouse, partner, or other family member
Sponsor: 
Yale University School of Medicine
Do you have alopecia areata? Does your child, spouse, partner, or other family member have alopecia areata? A research study being conducted at Yale University School of Medicine is currently recruiting participants for a research project that will study the impact of alopecia areata on quality of life. We are interested in learning about how alopecia areata affects the lives of both the people who live with it, as well as their loved ones. Your participation in this online survey will help raise awareness of the impact of alopecia areata on patients and families. The survey is completely...Read more

A Study with INCB018424 Phosphate Cream Applied Topically to Subjects with Alopecia Areata

Last Updated:
05/05/2016
Status:
Completed
Country:
United States
Drug:
INCB018424 Phosphate Cream
Administration:
Topical
Eligibility:
Age 18-70; diagnosed with patch type alopecia areata
Sponsor: 
Incyte Corporation
The purpose of this study is to find out if the drug INCB018424 Phosphate Cream is safe and has beneficial effects in people who have alopecia areata (partial or complete hair loss) when applied to the skin.Read more

A Study to Identify Autoimmune Epitopes in Alopecia Areata

Last Updated:
05/05/2016
Status:
Completed
Country:
United States
Eligibility:
Age 18+; diagnosed with alopecia areata, totalis or universalis
Sponsor: 
La Jolla Instistute for Allergy and Immunology
La Jolla Instistute for Allergy and Immunology is seeking volunteers to provide a standard blood donation for a study to better understand the immune response in alopecia areata. The purpose of this study is to identify and thoroughly characterize autoimmune epitopes present in alopecia areata. Understanding the pathophysiology of alopecia areata is essential for the development of future treatments and may help lead to better therapies for immune related hair loss in the future.Read more

A Study of the Lived Experience of Alopecia Areata Women

Last Updated:
07/22/2016
Status:
Completed
Country:
United States
Eligibility:
Women ages 30-35; diagnosed with alopecia areata, universalis or totalis in early adulthood
Sponsor: 
University of Minnesota
A research study being conducted at the University of Minnesota is seeking to better understand the experiences of women ages 30-35 who currently have alopecia areata (including universalis, or totalis), and developed their alopecia areata while in high school. By taking a small amount of your time to participate in this study you are helping uncover the story of what it is like to have alopecia areata. A $20 gift card will be provided to all participants as compensation for their time. Participants in the study are asked to take part in two interviews with the researcher. The interview can...Read more

A Study of Secukinumab for the Treatment of Alopecia Areata

Last Updated:
05/05/2016
Status:
Completed
Country:
United States
Drug:
Secukinumab
Administration:
Injection
Eligibility:
Age 18+; patch type alopecia areata
Sponsor: 
Icahn School of Medicine at Mount Sinai
Ichan School of Medicine at Mount Sinai is seeking volunteers for a study evaluating the effectiveness of a new study drug in the treatment of moderate to severe alopecia areata. The purpose of this study is t o assess the effects of a new treatment called secukinumab in patients with alopecia areata .Read more

Intralesional Steroids in the Treatment of Alopecia Areata

Last Updated:
05/05/2016
Status:
Recruiting
Country:
United States
Drug:
Intralesional Triamcinolone
Administration:
Injection
Eligibility:
Age 18-75; patch type alopecia areata
Sponsor: 
Columbia University
Intralesional steroids are the most commonly used treatment for alopecia areata, yet much remains unknown about the risks and benefits of different doses of intralesional steroids. The goal of this study is to answer some of those questions.Read more

Open-Label Single-Arm Clinical Trial to Evaluate The Efficacy of Abatacept in Moderate to Severe Patch Type Alopecia Areata

Last Updated:
05/05/2016
Status:
Completed
Country:
United States
Drug:
Abatacept
Administration:
Injection
Eligibility:
Age 18-75; patch type alopecia areata
Sponsor: 
Columbia University
Many people in the U.S. suffer from alopecia areata, yet treatment options are limited and sometimes painful. The goal of this study is to test a medication, given as a subcutaneous injection that acts on the immune system and may reverse hair loss.Read more

Pilot Study to Evaluate the Efficacy of Ruxolitinib in Alopecia Areata

Last Updated:
05/09/2016
Status:
Completed
Country:
United States
Drug:
Ruxolitinib
Administration:
Oral
Eligibility:
Age 18-75; patch type alopecia areata
Sponsor: 
Columbia University
Many people in the U.S. suffer from alopecia areata, yet treatment options are limited and sometimes painful. The goal of this study is to test a new medication taken as a pill that acts on the immune system and may reverse hair loss.Read more

The Family System and Alopecia Areata: A Phenomenological Study of Family Members' Lived Experiences

Last Updated:
05/05/2016
Status:
Completed
Country:
United States
Eligibility:
Age 18+; family member diagnosed with alopecia areata, totalis or universalis
A doctoral student is conducting voluntary confidential interviews to explore the experiences of family members of persons diagnosed with alopecia areata. The desired results of this study will aid family therapists and other professionals to better help those living with alopecia areata, as well as their families.Read more

Type 1 Diabetes TrialNet

Last Updated:
05/09/2016
Status:
Recruiting
Country:
United States
Eligibility:
Age 1-45 with 1st degree relative with T1D; Age 1-20 with 2nd/3rd degree relative with T1D
Sponsor: 
National Institute of Diabetes and Digestive and Kidney Diseases
Type 1 Diabetes TrialNet (TrialNet) is an international network of researchers who are exploring ways to prevent, delay and reverse the progression of type 1 diabetes. Alopecia Areata families have a higher incidence of other autoimmune diseases, including type 1 diabetes (T1D). Relatives of someone with T1D have 15 to 20 times the risk to develop the disease. TrialNet is offering T1D risk screening to blood relatives of someone with T1D through a blood test performed at no cost and available anywhere in the US.Read more

Pages